OTCMKTS:NMUS Nemus Bioscience (NMUS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Nemus Bioscience Stock (OTCMKTS:NMUS) 30 days 90 days 365 days Advanced Chart Get Nemus Bioscience alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume1.00 million shsAverage Volume377,395 shsMarket Capitalization$87.04 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewNemus Bioscience, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics. The company's product candidates in preclinical stage include NB1111 for the treatment of glaucoma; NB1222 used for treating chemotherapy induced nausea and vomiting; and NB3111 for the treatment of methicillin-resistant staphylococcus aureus. Its products under research comprise NB2111 for use in treating chemotherapy induced peripheral neuropathy; and NB2222 for the treatment of uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy. Nemus Bioscience, Inc. has a license agreement with the University of Mississippi to research, develop, and commercialize products for the treatment of infectious diseases. The company was founded in 2012 and is headquartered in Costa Mesa, California.Read More… Receive NMUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nemus Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address NMUS Stock News HeadlinesYield10 Bioscience, Inc. (YTEN)April 19, 2024 | finance.yahoo.comAssembly Biosciences Inc ASMBMarch 16, 2024 | morningstar.comDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election … surpassing $100,000 on Dec. 8 .… Now Juan believes it could hit $150,000 … or higher in 2025.May 5, 2025 | Weiss Ratings (Ad)Sagimet Biosciences Inc - Ordinary Shares - Class ASeptember 5, 2023 | money.usnews.comSatellos Bioscience Announces Closing of Previously Announced Non-Brokered Offering of $2.385 Million of Unsecured Non-Convertible DebenturesApril 27, 2023 | finance.yahoo.comCrown Bioscience Announces Transaction Closing of Indivumed's Service Business and Supporting BiobankApril 6, 2023 | finanznachrichten.dePsycheceutical Bioscience Provisional Patent Application for Novel Ketamine Topical for the Treatment of PTSDFebruary 24, 2023 | finance.yahoo.comSN BioScience and Boryung Announce the Licensing Agreement on Generic Version of AbraxaneJanuary 27, 2023 | finance.yahoo.comSee More Headlines NMUS Stock Analysis - Frequently Asked Questions How were Nemus Bioscience's earnings last quarter? Nemus Bioscience Inc (OTCMKTS:NMUS) posted its quarterly earnings results on Tuesday, May, 15th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter. How do I buy shares of Nemus Bioscience? Shares of NMUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nemus Bioscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nemus Bioscience investors own include Canopy Growth (CGC), Emerald Health Therapeutics (EMHTF), MedMen Enterprises (MMNFF), Aurora Cannabis (ACBFF), KushCo (KSHB), 22nd Century Group (XXII) and Cronos Group (CRON). Company Calendar Last Earnings5/15/2018Today5/04/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical Preparations Sub-IndustryCannabis Current SymbolOTCMKTS:NMUS CIKN/A Webwww.nemusbioscience.com Phone949-396-0330FaxN/AEmployees11Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,190,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-924.42% Debt Debt-to-Equity RatioN/A Current Ratio0.12 Quick Ratio0.12 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.12) per share Price / BookN/AMiscellaneous Outstanding Shares133,908,000Free FloatN/AMarket Cap$87.04 million OptionableNot Optionable Beta-0.04 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (OTCMKTS:NMUS) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nemus Bioscience Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Nemus Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.